Conclusion
migraine
MIGRAINE, DISEASE
This long-term extension study highlights eptinezumab as an effective and well-tolerated long-term preventive migraine treatment option for adults with a history of 2–4 prior preventive treatment failures. This study had high completion rates and demonstrated tolerability and benefits sustained for up to 18 months across migraine endpoints, including reductions in frequency and severity of migraine, reductions in acute medication use, high responder rates, and patient-reported improvements in functioning, disease status, and health-related quality of life.